Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics Plc ADR (NQ: BCYC )

17.49 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5
Open 17.49
Bid (Size) 16.68 (1)
Ask (Size) 17.82 (1)
Prev. Close 17.49
Today's Range 17.49 - 17.49
52wk Range 12.08 - 62.08
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Redhill Biopharma (NASDAQ:RDHL) stock moved upwards by 16.4% to $0.89 during Friday's pre-market session. The market value of their outstanding shares is at $47.6 million. As per the press... 
Via Benzinga
Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression
From Bicycle Therapeutics plc
Via Business Wire

Performance

YTD
-70.61%
-70.61%
1 Month
+26.10%
+26.10%
3 Month
-61.26%
-61.26%
6 Month
-70.61%
-70.61%
1 Year
-45.34%
-45.34%

More News

Read More
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
From Bicycle Therapeutics
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Bicycle Therapeutics's Return On Capital Employed Overview
Via Benzinga
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Analyst Ratings for Bicycle Therapeutics
Via Benzinga
Expert Ratings for Bicycle Therapeutics
Via Benzinga
Recap: Bicycle Therapeutics Q1 Earnings
Via Benzinga
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
B. Riley Securities Downgrades Rating to Neutral for Bicycle Therapeutics, Lowers Price Target To $33
Via Benzinga
Where Bicycle Therapeutics Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022
Via Benzinga
Why Bicycle Therapeutics Stock Is Soaring Today
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Via Benzinga
Will Bicycle Therapeutics, With A 25% Gain Today, Take On Pfizer In Covid?
Via Investor's Business Daily
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics's Return On Capital Employed Overview
Via Benzinga
What 4 Analyst Ratings Have To Say About Bicycle Therapeutics
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.